Jasper Therapeutics(US:JSPR) Newsfileยท2025-11-14 02:00Core Viewpoint - Rosen Law Firm is urging investors of Jasper Therapeutics, Inc. to secure legal counsel before the November 18, 2025 deadline for a securities class action lawsuit related to the company's alleged misleading statements and failures in manufacturing compliance [1][5]. Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3]. - The lawsuit claims that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and the implications for its product, briquilimab, which affected the company's financial and clinical prospects [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in achieving significant settlements for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and recovering over $438 million for investors in 2019 [4].